Statement: In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia.
Primary_evidence: Adverse Events 1:   Total: 6   Agranulocytosis 0/42 (0.00%)   Anaemia 2/42 (4.76%)   Febrile neutropenia 1/42 (2.38%)   Leukopenia 0/42 (0.00%)   Neutropenia 1/42 (2.38%)   Thrombocytopenia 1/42 (2.38%)   Cardio-respiratory arrest 0/42 (0.00%)   Pericardial effusion 1/42 (2.38%)   Gastric ulcer haemorrhage 0/42 (0.00%)   Melaena 0/42 (0.00%)   Fatigue 1/42 (2.38%)   Multi-organ failure 0/42 (0.00%) Adverse Events 2:   Total: 13   Agranulocytosis 1/61 (1.64%)   Anaemia 1/61 (1.64%)   Febrile neutropenia 0/61 (0.00%)   Leukopenia 2/61 (3.28%)   Neutropenia 2/61 (3.28%)   Thrombocytopenia 1/61 (1.64%)   Cardio-respiratory arrest 1/61 (1.64%)   Pericardial effusion 0/61 (0.00%)   Gastric ulcer haemorrhage 1/61 (1.64%)   Melaena 1/61 (1.64%)   Fatigue 1/61 (1.64%)   Multi-organ failure 1/61 (1.64%)
Secondary_evidence: Adverse Events 1:   Total: 17/145 (11.72%)   ANAEMIA 0/145 (0.00%)   LEUKOPENIA 2/145 (1.38%)   NEUTROPENIA 1/145 (0.69%)   LEUKOCYTOSIS 1/145 (0.69%)   THROMBOCYTOPENIA 1/145 (0.69%)   FEBRILE NEUTROPENIA 1/145 (0.69%)   THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%)   DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%)   CARDIAC FAILURE 1/145 (0.69%)   ATRIAL FIBRILLATION 1/145 (0.69%) Adverse Events 2:   Total: 11/144 (7.64%)   ANAEMIA 1/144 (0.69%)   LEUKOPENIA 0/144 (0.00%)   NEUTROPENIA 0/144 (0.00%)   LEUKOCYTOSIS 0/144 (0.00%)   THROMBOCYTOPENIA 0/144 (0.00%)   FEBRILE NEUTROPENIA 1/144 (0.69%)   THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)   DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%)   CARDIAC FAILURE 0/144 (0.00%)   ATRIAL FIBRILLATION 0/144 (0.00%)